A study is designed to evaluate the efficacy of a new drug, KM28. The study compares KM28 plus standard care verus standard care alone with regard to decreasing the incidence of recurrent breast cancer. The drug plus standard care will be approved if it decreases the rate of breast cancer recurrence by at least 40% compared to standard therapy alone. The reucrrence rate on standard therapy is 8%. In order to approve KM28, what's the maximal incidence of recurrent disease acceptable for women treated with KM28 plus standard therapy?
The answer is 4.8%